253 related articles for article (PubMed ID: 12825872)
21. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
[TBL] [Abstract][Full Text] [Related]
22. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
23. What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy?
van Dam L; Korfage IJ; Kuipers EJ; Hol L; van Roon AH; Reijerink JC; van Ballegooijen M; van Leerdam ME
Eur J Cancer; 2013 Jul; 49(10):2321-30. PubMed ID: 23571149
[TBL] [Abstract][Full Text] [Related]
24. Systematic review of the effectiveness of population screening for colorectal cancer.
Kerr J; Day P; Broadstock M; Weir R; Bidwell S
N Z Med J; 2007 Jul; 120(1258):U2629. PubMed ID: 17653247
[TBL] [Abstract][Full Text] [Related]
25. Inter-endoscopist variation in polyp and neoplasia pick-up rates in flexible sigmoidoscopy screening for colorectal cancer.
Bretthauer M; Skovlund E; Grotmol T; Thiis-Evensen E; Gondal G; Huppertz-Hauss G; Efskind P; Hofstad B; Thorp Holmsen S; Eide TJ; Hoff G
Scand J Gastroenterol; 2003 Dec; 38(12):1268-74. PubMed ID: 14750648
[TBL] [Abstract][Full Text] [Related]
26. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial.
Holme Ø; Løberg M; Kalager M; Bretthauer M; Hernán MA; Aas E; Eide TJ; Skovlund E; Schneede J; Tveit KM; Hoff G
JAMA; 2014 Aug; 312(6):606-15. PubMed ID: 25117129
[TBL] [Abstract][Full Text] [Related]
27. A community-based program of colorectal screening in an asymptomatic population: evaluation of screening tests and compliance.
Bat L; Pines A; Ron E; Niv Y; Arditi E; Shemesh E
Am J Gastroenterol; 1986 Aug; 81(8):647-51. PubMed ID: 3740023
[TBL] [Abstract][Full Text] [Related]
28. Small adenomas detected during fecal occult blood test screening for colorectal cancer. The impact of serendipity.
Ransohoff DF; Lang CA
JAMA; 1990 Jul; 264(1):76-8. PubMed ID: 2192093
[TBL] [Abstract][Full Text] [Related]
29. [Colonoscopic screening in first-degree relatives of patients with sporadic colorectal cancer].
Scintu F; Canalis C; Capra F; D'Alia G; Giordano M; Mocci P; Pisano M; Casula G
Ann Ital Chir; 2000; 71(6):693-9. PubMed ID: 11347322
[TBL] [Abstract][Full Text] [Related]
30. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial.
Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Church T; Yurgalevitch S; Austin JH; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Jul; 97(13):989-97. PubMed ID: 15998952
[TBL] [Abstract][Full Text] [Related]
31. Contribution of the OC Sensor
Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
[TBL] [Abstract][Full Text] [Related]
32. Estimation of overdiagnosis in colorectal cancer screening with sigmoidoscopy and faecal occult blood testing: comparison of simulation models.
Wieszczy P; Kaminski MF; Løberg M; Bugajski M; Bretthauer M; Kalager M
BMJ Open; 2021 Apr; 11(4):e042158. PubMed ID: 33853794
[TBL] [Abstract][Full Text] [Related]
33. Colorectal cancer screening.
Bretthauer M
J Intern Med; 2011 Aug; 270(2):87-98. PubMed ID: 21575082
[TBL] [Abstract][Full Text] [Related]
34. Randomized controlled trial: Flexible sigmoidoscopy as an adjunct to faecal occult blood testing in population screening.
Steele RJ; Carey FA; Stanners G; Lang J; Brand J; Brownlee LA; Crichton EM; Winter JW; Phull PS; Mowat C; Strachan JA; Digan AM; Fraser CG
J Med Screen; 2020 Jun; 27(2):59-67. PubMed ID: 31690179
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of screening for colorectal cancer in the general population.
Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
[TBL] [Abstract][Full Text] [Related]
36. Screening for gastrointestinal neoplasia: efficacy and cost of two different approaches in a clinical rehabilitation centre.
Manus B; Brägelmann R; Armbrecht U; Stolte M; Stockbrügger RW
Eur J Cancer Prev; 1996 Feb; 5(1):49-55. PubMed ID: 8664809
[TBL] [Abstract][Full Text] [Related]
37. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
[TBL] [Abstract][Full Text] [Related]
38. Possible advantages and drawbacks of adding flexible sigmoidoscopy to hemoccult-II in screening for colorectal cancer. A randomized study.
Rasmussen M; Kronborg O; Fenger C; Jørgensen OD
Scand J Gastroenterol; 1999 Jan; 34(1):73-8. PubMed ID: 10048736
[TBL] [Abstract][Full Text] [Related]
39. Offering people a choice for colorectal cancer screening.
Senore C; Ederle A; Benazzato L; Arrigoni A; Silvani M; Fantin A; Fracchia M; Armaroli P; Segnan N
Gut; 2013 May; 62(5):735-40. PubMed ID: 22442162
[TBL] [Abstract][Full Text] [Related]
40. Long-term risk of colorectal cancer after screen-detected adenoma: Experiences from a Danish gFOBT-positive screening cohort.
Bjerrum A; Lindebjerg J; Andersen O; Fischer A; Lynge E
Int J Cancer; 2020 Aug; 147(4):940-947. PubMed ID: 31894860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
